Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, is pleased to announce that the Company has entered into a strategic partnership agreement (“the Agreement”) with Eyebright Medical (Beijing) Co., Ltd. (“Eyebright Medical”, Shanghai STAR Market: 688050), a Beijing-based pharmaceutical company focusing on the research and development, manufacturing and commercialization of ophthalmic medical devices. Zhaoke Ophthalmology and Eyebright Medical will collaborate on various aspects of ophthalmology such as drugs and medical devices.
According to the Agreement, Zhaoke Ophthalmology and Eyebright Medical will have comprehensive collaborations in the ophthalmology field. The two parties will also explore opportunities to research, develop and commercialize ophthalmic products together, as well as promote Zhaoke Ophthalmology’s products – including ophthalmic medical care, myopia progression control and vision care products – in eye hospitals, ophthalmic clinics, vision centres, and other terminal channels, in order to achieve a mutually beneficial goal by leveraging both companies’ edges and strengths.
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology (left) and Dr. Xie Jiangbing, Chairman and General Manager of Eyebright Medical (right) signed the strategic partnership agreement.
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, stated, “We are pleased to become strategic partners with Eyebright Medical. Zhaoke Ophthalmology has always adhered to the R&D and commercialization of ophthalmic drugs, including our innovative drug for dry eye disease, CsA Ophthalmic Gel, for which we have submitted a new drug application to the National Medical Products Administration of China, as well as NVK002, an innovative drug currently undergoing phase III clinical trial for the treatment of myopia progression control for children and adolescents. Eyebright Medical is an innovation-driven medical device manufacturer. It highly synergizes with Zhaoke on multiple aspects including R&D, product development and commercialization of areas such as vision protection, ophthalmic disease treatment and myopia prevention. We look forward to partnering with Eyebright Medical to jointly contribute to the Chinese ophthalmic sector.”
Feng Jiang, Sales & Marketing Senior Vice President of Zhaoke Ophthalmology, said, “Commercialization has always been one of Zhaoke’s pivotal strategies. We have been establishing an omni-channel strategy that combines both online and offline approaches, not only establishing friendly relationships with traditional channels such as public hospitals and private ophthalmic institutions, but also strengthening brand awareness online through digital, social and e-commerce channels. We hope that by partnering with Eyebright Medical and leveraging our omni-channel strategy, we can provide ophthalmic patients with a more comprehensive product portfolio and purchasing channels, and rapidly bring improvement to the visual health of the public.”
Dr. Xie Jiangbing, Chairman and General Manager of Eyebright Medical, says, “Zhaoke Ophthalmology and Eyebright Medical are listed on the Hong Kong Stock Exchange and the Shanghai STAR Market respectively. We are both R&D and innovative driven, our products are highly complementary, and we can share sales channels. The team members of both parties have a high degree of harmony and a strong willingness to cooperate, and as a result, a partnership agreement was quickly reached. It is believed that this collaboration will have an important impact on the Chinese ophthalmology sector, and we also look forward to the approval of Zhaoke's blockbuster products and early contribution to the protection of the eye health of Chinese patients.”
Jia Baoshan, Deputy General Manager and Marketing Sales Director of Eyebright Medical, commented, “Eyebright Medical has been deeply involved in the market of intraocular lenses for cataract for ten years, and has established a strong channel strategy to effectively access end-users. Our orthokeratology lens has also experienced four years of rapid growth since its launch, and also has extensive channel resources and nearly one million users. Zhaoke Ophthalmology’s rich drug pipeline and multiple featured products, and our existing optometry products would be complimentary advantages to both companies. The application of orthokeratology lenses and defocusing lenses, combined with low-concentration atropine improves the effectiveness of myopia prevention and control, and there has been a consensus in clinical and academic community around that. We believe that along with the launches of Zhaoke Ophthalmology’s products, more patients will benefit from the support of Eyebright Medical’s efficient channels.”
- End -
About Eyebright Medical
Eyebright Medical Technology (Beijing) Ltd. is a National High-tech Enterprise located in Zhongguancun Science and Technology Park, Beijing, China. The company is listed in Shanghai Stock Exchange market with the trading code of 688050.
Focusing on the protection and caring of human eyes and vision health, the company aims to provide first class medical products and services to global ophthalmology surgeons, patients and consumers. The company has been developing a full range of ophthalmic medical products, which include surgical implants, surgical instruments, equipment, optometric lenses, eye drops etc., for the treatment of cataract, glaucoma, refractive errors and many other ophthalmic diseases.
Eyebright is committed to the mission of developing innovative new technologies and products. As a Joint Laboratory of National Engineering Research Center for Ophthalmic Equipment in China, Eyebright owns the most advanced R&D facilities and equipment, and forms a multi-disciplinary professional team including engineers and scientists from material, optical, mechanical and clinical research fields. The company’s research work has applied for more than 100 patents worldwide.
